ATE314860T1 - Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet - Google Patents
Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaetInfo
- Publication number
- ATE314860T1 ATE314860T1 AT01906632T AT01906632T ATE314860T1 AT E314860 T1 ATE314860 T1 AT E314860T1 AT 01906632 T AT01906632 T AT 01906632T AT 01906632 T AT01906632 T AT 01906632T AT E314860 T1 ATE314860 T1 AT E314860T1
- Authority
- AT
- Austria
- Prior art keywords
- cop
- nervous system
- peptide
- polypeptide
- polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20979900P | 2000-06-07 | 2000-06-07 | |
| US62021600A | 2000-07-20 | 2000-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE314860T1 true ATE314860T1 (de) | 2006-02-15 |
Family
ID=26904524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01906632T ATE314860T1 (de) | 2000-06-07 | 2001-01-22 | Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020037848A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1294390B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4328090B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20030007397A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100438906C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE314860T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU783031B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2398277C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1105263T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60116467T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1294390T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2256200T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL150801A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02007109A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ520282A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001093893A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| CA2411536A1 (en) * | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1459065B1 (en) | 2001-12-04 | 2010-07-28 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) * | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| WO2004060265A2 (en) * | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| CN1886506B (zh) * | 2003-09-29 | 2012-05-30 | 中外制药株式会社 | 在nk细胞中表达的蛋白质 |
| WO2005032482A2 (en) * | 2003-10-03 | 2005-04-14 | Bayhill Therapeutics, Inc. | Treatment of demyelinating autoimmune disease with modified ordered peptides |
| CA2546077C (en) * | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| DK1701730T3 (da) * | 2003-12-09 | 2013-11-25 | Yeda Res & Dev | Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser |
| CA2565819A1 (en) | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| DK1799703T3 (da) | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| ES2541780T3 (es) * | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| JP2009536157A (ja) | 2006-04-13 | 2009-10-08 | ペプチミューン,インコーポレイテッド | エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法 |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| RS55607B1 (sr) | 2009-08-20 | 2017-06-30 | Yeda Research & Development Company Ltd | Niskofrekventna terapija glatiramer acetatom |
| WO2011080733A1 (en) | 2010-01-04 | 2011-07-07 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| EP2892353A4 (en) | 2012-09-10 | 2016-10-26 | Yeda Res & Dev | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| EP4340853A4 (en) * | 2021-05-20 | 2025-05-07 | Washington University | Neuroprotective compositions and methods |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN121517513A (zh) * | 2025-11-20 | 2026-02-13 | 西湖大学 | 一种共聚物多肽及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| JP2002503658A (ja) * | 1998-02-13 | 2002-02-05 | オートイミューン インク | COP−1及びTh−2促進性サイトカインを使用した、多発性硬化症の治療 |
-
2001
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en not_active Ceased
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Ceased
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU783031B2 (en) | 2005-09-15 |
| DE60116467T2 (de) | 2006-11-02 |
| EP1294390A2 (en) | 2003-03-26 |
| EP1294390B1 (en) | 2006-01-04 |
| CA2398277A1 (en) | 2001-12-13 |
| MXPA02007109A (es) | 2002-12-13 |
| DE60116467D1 (de) | 2006-03-30 |
| CY1105263T1 (el) | 2010-03-03 |
| JP2004507460A (ja) | 2004-03-11 |
| IL150801A (en) | 2007-10-31 |
| JP4328090B2 (ja) | 2009-09-09 |
| CN1462190A (zh) | 2003-12-17 |
| NZ520282A (en) | 2004-09-24 |
| CN100438906C (zh) | 2008-12-03 |
| AU3451801A (en) | 2001-12-17 |
| IL150801A0 (en) | 2003-02-12 |
| WO2001093893A3 (en) | 2002-04-04 |
| HK1058892A1 (zh) | 2004-06-11 |
| ES2256200T3 (es) | 2006-07-16 |
| CA2398277C (en) | 2013-09-03 |
| KR20030007397A (ko) | 2003-01-23 |
| US20020037848A1 (en) | 2002-03-28 |
| WO2001093893A2 (en) | 2001-12-13 |
| DK1294390T3 (da) | 2006-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60116467D1 (de) | Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet | |
| DE60112718D1 (de) | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie | |
| WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
| DE69835279D1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| CY1111120T1 (el) | Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση | |
| IL161591A0 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| DE69630890D1 (de) | Peptid-immitierende substanzen in der krebstherapie | |
| DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
| WO2003008443A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
| DE60230807D1 (de) | Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha | |
| DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| EP1351968A4 (en) | MUTATIONS IN THE ALPHA1 SUBUNIT OF THE NEURONAL GENE SODIUM CHANNEL, ASSOCIATED POLYPEPTIDES, AND TREATMENT OF GEFS + SYNDROME (GENERALIZED EPILEPSY WITH FEBRILIS + CRISIS) | |
| ATE500328T1 (de) | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion | |
| ATE356145T1 (de) | Polypeptide zur regenerierung des nervensystems | |
| ATE490972T1 (de) | Biologisch aktive peptide und deren verwendung zur reparatur verletzter nerven | |
| RU96114420A (ru) | Способ лечения больных с неврологическими проявлениями остеохондроза позвоночника | |
| WO2024040030A3 (en) | Treating protein misfolding disorders | |
| EP1714979A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| 王一菱 et al. | Relationship between Acupuncture Analgesia and Met-Enkephalin or Dynorphin | |
| DE50201092D1 (de) | Verwendung eines Fibroblastenwachstumsfaktor-Bindeproteins zur Behandlung und Diagnose von diabetischen Wundheilugnsstörungen | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1294390 Country of ref document: EP |